When is a point of view a conflict of interest?

BMJ (Online)

Volumn 355, Issue , 2016, Pages

  Lenzer, Jeanne ^a  

^a BMJ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; PRASUGREL; ROFECOXIB; VALDECOXIB; VARENICLINE;

ARTICLE; CONFLICT OF INTEREST; DEVICE APPROVAL; DRUG APPROVAL; DRUG RECALL; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HUMAN; ORTHOPEDIC EQUIPMENT; PERCEPTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ADVISORY COMMITTEE; DRUG INDUSTRY; ETHICS; UNITED STATES;

ADVISORY COMMITTEES; CONFLICT OF INTEREST; DEVICE APPROVAL; DRUG APPROVAL; DRUG INDUSTRY; GUIDELINES AS TOPIC; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84999634047     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i6194     Document Type: Article

References (23)

1. US Food and Drug Administration. Guidance for the public, FDA advisory committee members, and FDA staff on procedures for determining conflict of interest and eligibility for participation in FDA Advisory Committees.2008. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM125646.pdf.
2. Procedures for evaluating appearance issues and granting authorizations for participation in Food and Drug Administration advisory committees; draft guidance for the public, Food and Drug Administration advisory committee members, and Food and Drug administration staff. 2016. www.fda.gov/downloads/regulatoryinformation/guidances/ucm508852.pdf.
3. Ortwerth M. FDA advisory committee members and "appearance issues." 29 Jun 2016. http://blogs.fda.gov/fdavoice/index.php/2016/06/fda-advisory-committee-members-andappearance-issues/.
4. Floyd J, Wolfe S. Letter to FDA about safety of prasugrel (Effient) and removal of advisory committee member. 2009. http://www.citizen.org/Page.aspxpid=605
5. O'Riordan M. "Mistakes" made: FDA acknowledges Lilly phoned to question Sanjay Kaul's inclusion on prasugrel panel. Heartwire 2009 Feb 20. http://www.medscape.com/viewarticle/588550.
6. Red flags raised over FDA advisory-panel hearing on prasugrel. Medscape 2009.http://www.medscape.com/viewarticle/588288
7. Husten L. Transcript of FDA February 23 news conference on prasugrel advisory panel. CardioBrief 2009 Feb 26. http://cardiobrief.org/2009/02/26/transcript-of-fda-february-23-news-conference-on-prasugrel-advisory-panel/
8. Lenzer J. FDA bars own expert from evaluating risks of painkillers. BMJ 2004;329:1203. doi:10.1136/bmj.329.7476.1203 pmid:15550413.
9. Union of Concerned Scientists. FDA medical device approval based on politics, not science. 2009. http://www.ucsusa.org/our-work/center-science-and-democracy/promotingscientific-integrity/fda-medical-device-approval.html#.V4apZzWi4ZE
10. Layton L. FDA look again at knee implant after reports of pressure. Washington Post 2009 Sep 25. http://www.washingtonpost.com/wp-dyn/content/article/2009/09/24/AR2009092404272.html
11. Harris G, Halbfinger DM. FDA reveals it fell to a push by lawmakers. New York Times 2009 Sep 24. http://www.nytimes.com/2009/09/25/health/policy/25knee.html-r=0.
12. Lenzer J, Epstein K. The Yaz men: members of FDA panel reviewing the risks of popular Bayer contraceptive had industry ties. Wash Mon 2012 Jan 9. http://www. washingtonmonthly.com/ten-miles-square/2012/01/the-yaz-men-members-of-fda-pan034651.php
13. Wolfe S. Removal of consumer advocate from Dec 8 advisory committee meeting is bad policy. Public Citizen Health Research Group, 2011. http://archive.commercialalert.org/issues/health/drug-marketing/removal-of-consumer-advocate-from-dec-8-advisorycommittee-meeting-is-bad-policy
14. Lurie P. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings. MedGenMed 2006;8:22.pmid:17415305.
15. Steinbrook R. Financial conflicts of interest and the Food and Drug Administration's advisory committees. N Engl J Med 2005;353:116-8. doi:10.1056/NEJMp058108 pmid: 16014880.
16. Cauchon D. FDA advisers tied to industry. USA Today 2000 Sep 25. http://www. internetwks.com/pauling/fdaconflict.html
17. Brody H. Intellectual conflict of interest rides again. Hooked: Ethics, Medicine, and Pharma 2011 Dec 9. http://brodyhooked.blogspot.com/2011/12/intellectual-conflict-of-interestrides. html.
18. Shawwa K, Kallas R, Koujanian S, et al. Requirements of clinical journals for authors' disclosure of financial and non-financial conflicts of interest: a cross sectional study. PLoS One 2016;11:e0152301. doi:10.1371/journal.pone.0152301 pmid:27030966.
19. Laupacis A, Born K. Conflicts of interest don't always involve money. KevinMD 2012 Feb 10. http://www.kevinmd.com/blog/2012/02/conflicts-interest-involve-money.html
20. Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ 2015;350:h2942. doi:10.1136/bmj.h2942 pmid:26036926.
21. Rosenbaum L. Understanding bias-the case for careful study. N Engl J Med 2015;372:1959-63. doi:10.1056/NEJMms1502497 pmid:25970055.
22. Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011;6:e27016. doi:10.1371/journal.pone.0027016 pmid:22073240.
23. Lenzer J, Brownlee S. Naming names: is there an (unbiased) doctor in the houseBMJ 2008;337:a930. doi:10.1136/bmj.a930 pmid:18650241